Alzheimer's Blood Test Deployment Network
A specialized clinical lab network that partners with primary care practices, geriatric clinics, and memory centers to offer rapid phosphorylated tau and amyloid blood biomarker testing with 48-72 hour turnaround and integrated result interpretation. The service handles specimen collection training, quality control, result delivery, and physician education—turning existing clinics into early-detection sites without requiring new infrastructure or expensive imaging.
44 weeks • 70% confidence
Value Proposition
Eliminates 3-6 month diagnostic delays by moving testing from specialty imaging centers into routine primary care; reduces patient cost from $3,000-$8,000 (PET/MRI) to $400-$600 per test; captures patients at earliest symptomatic stage when lecanemab and donanemab show highest efficacy; practices bill insurance directly, improving cash flow vs. referral-dependent model.
Target Audience
Primary care practices, geriatric medicine clinics, and memory disorder specialists in underserved/rural areas; practices with 500+ Medicare patients aged 60+
Key Features
- Turnkey phlebotomy training program for clinic staff (2-day certification)
- Standardized pre-analytical specimen handling kit (temperature-controlled transport)
- CLIA-certified central lab with ISO 15189 accreditation for biomarker analysis
- And more, with full implementation detail...
Tech Stack
Unlock the full solution
You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.
Sign up free to continue3 free solution credits on signup
The build plan is behind the wall
Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.
Sign up freeOriginal Problem
Delayed Alzheimer's diagnosis leads to missed treatment windows and accelerated cognitive declinePatients and families experience agonizing uncertainty waiting months for definitive Alzheimer's diagnosis through expensive PET/MRI scans and cognitive testing, during which irreversible neurodegeneration progresses unchecked. Current diagnostic pathways are slow, costly, and inaccessible in routine clinical settings, forcing patients into advanced stages before confirmation. A rapid, accurate blood test could enable early intervention when treatments are most effective, but this capability hasn't yet reached everyday clinical practice.
Score: 17.5%